文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

蛇咬伤相关血栓性微血管病:澳大利亚前瞻性队列研究

Snakebite-associated thrombotic microangiopathy: an Australian prospective cohort study [ASP30].
PubMed 文献 · Clin Toxicol (Phila) · 2021-07-30
一句话结论蛇咬伤相关TMA定义为贫血伴裂红细胞且血小板减少或血小板下降>25%,AKI常见但多数可脱离透析,TPE对透析依赖AKI无获益证据。

澳大利亚蛇咬伤项目前瞻性纳入2069例疑似蛇咬伤患者,其中1158例全身中毒,842例发生VICC,104例(12.4%)发生TMA。TMA患者AKI发生率94%,34%需透析,4例死亡;透析依赖AKI患者最终无透析生存率97%,但52%随访者存在≥3期CKD。TPE用于5例透析依赖AKI患者,无透析生存或脱离透析时间无显著差异。研究支持TMA定义为贫血伴裂红细胞且血小板减少或血小板下降>25%。

要点

  • 蛇咬伤相关TMA定义为贫血伴裂红细胞,且血小板减少或血小板计数较基线下降>25%。
  • 全身中毒患者中TMA发生率12.4%,不同蛇种差异明显:太攀蛇26%、棕蛇17%、虎蛇8%。
  • TMA患者AKI发生率94%,34%需透析,透析依赖AKI患者最终无透析生存率97%。
  • 透析依赖AKI的TMA患者中,TPE对无透析生存或脱离透析时间无显著改善。
  • 存活透析依赖AKI患者长期随访52%存在≥3期CKD,无终末期肾病。

适用人群与场景

  • 澳大利亚202家医院前瞻性队列中疑似或确诊蛇咬伤患者,2004-2018年纳入。
  • 分析对象为全身中毒且发生VICC的患者,其中部分发生TMA。

诊断标准与关键阈值

  • TMA定义为贫血伴裂红细胞(schistocytosis)。
  • 研究支持的定义为贫血伴裂红细胞且满足以下之一:血小板减少或血小板计数较基线下降>25%。
  • AKI为TMA最常见的终末器官表现;透析依赖AKI指需要透析的AKI。

处置流程与药物剂量

  • 原文未提及具体抗蛇毒血清或TPE的剂量、途径、频次方案。
  • TPE用于5例透析依赖AKI的TMA患者,但与无透析生存或脱离透析时间无显著差异。

红旗征与不能漏的情况

  • 蛇咬伤后出现贫血伴裂红细胞提示TMA,需警惕AKI。
  • TMA患者中90%存在血小板减少,另有8%血小板较就诊时下降>25%。
  • TMA患者AKI发生率94%,34%需透析,4例死亡。

研究设计与关键结果

  • 前瞻性队列研究,202家澳大利亚医院,纳入2069例疑似蛇咬伤患者。
  • 1158例(56.0%)全身中毒,其中842例(72.7%)发生VICC,104例(12.4%)发生TMA。
  • TMA发生率:太攀蛇26%(13/50)、棕蛇17%(60/351)、虎蛇8%(16/197)。
  • TMA患者年龄大于非TMA的VICC患者(中位53岁 vs 41岁,p<0.0001)。
  • TMA患者AKI发生率94%(98/104),透析依赖AKI 34%(33/98),死亡4例。
  • 透析依赖AKI的TMA患者最终无透析生存率97%(32/33)。
  • TPE用于5例透析依赖AKI患者,无透析生存或脱离透析时间无显著差异。
  • 25例透析依赖AKI患者随访>90天(130人年),无终末期肾病,但52%(13/25)存在≥3期CKD。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究(澳大利亚蛇咬伤项目)。
  • 局限:观察性设计,TPE分析样本量小(5例),无法排除混杂。

对床旁实践的改变

  • 蛇咬伤后应监测贫血、裂红细胞、血小板和肾功能,以识别TMA和AKI。
  • TMA定义可采用贫血伴裂红细胞且血小板减少或血小板下降>25%。
  • 透析依赖AKI的TMA患者多数可脱离透析,但需关注长期CKD风险。
  • TPE不应常规用于蛇咬伤相关TMA的透析依赖AKI,因无获益证据。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Snakebite-associated thrombotic microangiopathy (TMA) occurs in a subset of patients with venom-induced consumption coagulopathy (VICC) following snakebite. Acute kidney injury (AKI) is the commonest end-organ manifestation of TMA. The epidemiology, diagnostic features, outcomes, and effectiveness of interventions including therapeutic plasma-exchange (TPE), in snakebite-associated TMA are poorly understood.

METHODS: We reviewed all patients with suspected or confirmed snakebite recruited to the Australian Snakebite Project (2004-2018 inclusive), a prospective cohort study, from 202 participating Australian hospitals across the country. TMA was defined as anemia with schistocytosis.

RESULTS: 2069 patients with suspected snakebite were enrolled, with 1158 (56.0%) systemically envenomed, of which 842 (72.7%) developed VICC, from which 104 (12.4%) developed TMA. Of those systemically envenomed, TMA occurred in 26% (13/50) taipan, 17% (60/351) brown, and 8% (16/197) tiger snakebites. Thrombocytopenia was present in 90% (94/104) of TMA cases, and a further eight (8%) had a > 25% decrease in platelets from the presentation. Patients with TMA were significantly older than non-TMA patients with VICC (53 [35-61] versus 41 [24-55] years, median [IQR], p < 0.0001). AKI developed in 94% (98/104) of TMA patients, with 34% (33/98) requiring dialysis (D-AKI). There were four deaths. In D-AKI TMA cases, eventual dialysis-free survival (DFS) was 97% (32/33). TPE was used in five D-AKI cases, with no significant difference in DFS or time to independence from dialysis. >90-day follow-up for 25 D-AKI cases (130 person-years) showed no end-stage kidney disease but 52% (13/25) had ≥ stage 3 chronic kidney disease (CKD).

CONCLUSION: Our findings support a definition of snakebite-associated TMA as anemia with schistocytosis and either thrombocytopenia or >25% drop in platelet count. AKI occurring with snakebite-associated TMA varied in severity, with most achieving DFS, but with a risk of long-term CKD in half. We found no evidence of benefit for TPE in D-AKI.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Noutsos T, Currie BJ, Isoardi KZ, et al. Snakebite-associated thrombotic microangiopathy: an Australian prospective cohort study [ASP30]. Clin Toxicol (Phila). 2021. PMID: 34328386. doi:10.1080/15563650.2021.1948559

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。